Larimar Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Larimar Therapeutics, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Early-stage biotech with validated rare disease treatment candidate approaching potential FDA approval, but capital-constrained and unprofitable with significant execution risk. Larimar received FDA Breakthrough Therapy Designation for nomlabofusp for Friedreich's ataxia. Clinical data shows 100% of 10 participants achieving skin frataxin (FXN) >50% of healthy median at 6 months.
What is Larimar Therapeutics, Inc.'s industry? Larimar Therapeutics, Inc. (larimartx.com) operates in Biotechnology - Rare Disease Therapeutics. AskCyborg classifies Larimar Therapeutics, Inc. under Biotechnology - Rare Disease Therapeutics in its company registry.
Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead compound, nomlabofusp, is in dev...
Cyborg Score thesis
Early-stage biotech with validated rare disease treatment candidate approaching potential FDA approval, but capital-constrained...
Read the full analyst-debate transcript →Get the Latest Larimar Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeLarimar Therapeutics, Inc. Overview
Pro stress-test →Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead compound, nomlabofusp, is in development as a potential treatment for Friedreich's ataxia (FA). The company recently achieved a major regulatory milestone with significant clinical validation.
Strategic Profile
Pro stress-test →The FDA granted Breakthrough Therapy Designation for nomlabofusp for adults and children with Friedreich's ataxia, and the FDA and company aligned on using skin FXN as a potential surrogate endpoint to support a planned BLA seeking accelerated approval in June 2026. Topline open-label study data to support the BLA are expected in Q2 2026, a global Phase 3 will be underway at submission, and a U.S. launch is targeted in H1 2027 if approved.
Competitive Landscape
Pro stress-test →Larimar is trading at US$3.69 versus an analyst price target of US$16.30. The company operates in the rare disease biotech space focused on protein replacement therapies. Competitors would include other companies developing treatments for mitochondrial disorders and genetic rare diseases, though Larimar's specific nomlabofusp candidate appears positioned as a potential first-to-market option for Friedreich's ataxia.
Industry Context
Larimar Therapeutics, Inc. operates in Biotechnology - Rare Disease Therapeutics.
Key facts
Founded: 2005 · Headquarters: Bala Cynwyd, Pennsylvania, United States · Employees: 65 · Revenue: $0 · Market cap: $454.49M